Trial reportEuropean journal of nuclear medicine and molecular imaging2011
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.
Trial report in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
167 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- Prospective study onBritish journal of cancer · 2026Trial
- Clinicopathological and molecular predictors of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Trial
- Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer.BMC medical imaging · 2018Trial
- Trial
- CONSORT-Independent prognostic value of asphericity of pretherapeutic F-18 FDG uptake by primary tumors in patients with breast cancer.Medicine · 2017Trial
- Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed withEuropean journal of nuclear medicine and molecular imaging · 2017Trial
- Trial
- The Role ofMolecular imaging and radionuclide therapy · 2026Article
- Prognostic relevance of [18F]FDG PET/CT in triple-negative breast cancer: Results from the triple negative (TRINE)-PET trial.European journal of nuclear medicine and molecular imaging · 2026Article
- Diagnostic value of [Scientific reports · 2026Observational
- Do new guidelines enable a more accurate comparison of [Breast cancer research : BCR · 2026Article
- Integrating machine learning with histopathological, immunohistochemical, and PET parameters in the study of invasive breast carcinoma, no special type.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [ 18 F] fluorodeoxyglucose PET.Nuclear medicine communications · 2026Article
- Positron-emission tomography as a predictor of response to first-line cyclin-dependent kinase 4/6 inhibitors in patients with metastatic ER-positive HER2-negative breast cancer.NPJ breast cancer · 2026Article
- Comparative evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- Comparison between [EJNMMI research · 2026Article
- Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT.Annals of nuclear medicine · 2026Article
- FDG PET/CT in the post-treatment evaluation of breast cancer: an emphasis on triple-negative breast cancer.American journal of nuclear medicine and molecular imaging · 2026Review
107 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to determine the impact of the main clinicopathological and biological prognostic factors of breast cancer on (18)F-fluorodeoxyglucose (FDG) uptake. Only women with tumours larger than 20 mm (T2-T4) were included in order to minimize bias of partial volume effect.
methodsIn this prospective study, 132 consecutive women received FDG PET/CT imaging before starting neoadjuvant chemotherapy. Maximum standardized uptake values (SUV(max)) were compared to tumour characteristics as assessed on core biopsy.
resultsThere was no influence of T and N stage on SUV. Invasive ductal carcinoma showed higher SUV than lobular carcinoma. However, the highest uptake was found for metaplastic tumours, representing 5% of patients in this series. Several biological features usually considered as bad prognostic factors were associated with an increase in FDG uptake: the median of SUV(max) was 9.7 for grade 3 tumours vs 4.8 for the lower grades (p < 0.0001); negativity for oestrogen receptors (ER) was associated with higher SUV (ER+ SUV = 5.5; ER- SUV = 7.6; p = 0.003); triple-negative tumours (oestrogen and progesterone receptor negative, no overexpression of c-erbB-2) had an SUV of 9.2 vs 5.8 for all others (p = 0005); p53 mutated tumours also had significantly higher SUV (7.8 vs 5.0; p < 0.0001). Overexpression of c-erbB-2 had no effect on the SUV value.
conclusionKnowledge of the factors influencing uptake is important when interpreting FDG PET/CT scans. Also, findings that FDG uptake is highest in those patients with poor prognostic features (high grade, hormone receptor negativity, triple negativity, metaplastic tumours) is helpful to determine who are the best candidates for baseline staging.
Indexed as
Identifiers
21057787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.